View on Pubmed.gov 34548489 | View on doi.org 10.1038/s41467-...
SON drives oncogenic RNA splicing in glioblastoma by regulating PTBP1/PTBP2 switching and RBFOX2 activity.
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA. Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, USA.
- Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, USA.
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
- Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, USA.
- Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA. rwsobol@southalabama.edu.
- Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, USA. rwsobol@southalabama.edu.
- Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, USA. stlim@southalabama.edu.
- Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, USA. eyahn@uabmc.edu.
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. eyahn@uabmc.edu.
Abstract
While dysregulation of RNA splicing has been recognized as an emerging target for cancer therapy, the functional significance of RNA splicing and individual splicing factors in brain tumors is poorly understood. Here, we identify SON as a master regulator that activates PTBP1-mediated oncogenic splicing while suppressing RBFOX2-mediated non-oncogenic neuronal splicing in glioblastoma multiforme (GBM). SON is overexpressed in GBM patients and SON knockdown causes failure in intron removal from the PTBP1 transcript, resulting in PTBP1 downregulation and inhibition of its downstream oncogenic splicing. Furthermore, SON forms a complex with hnRNP A2B1 and antagonizes RBFOX2, which leads to skipping of RBFOX2-targeted cassette exons, including the PTBP2 neuronal exon. SON knockdown inhibits proliferation and clonogenicity of GBM cells in vitro and significantly suppresses tumor growth in orthotopic xenografts in vivo. Collectively, our study reveals that SON-mediated RNA splicing is a GBM vulnerability, implicating SON as a potential therapeutic target in brain tumors.
References
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1894-9
Genes Dev. 2015 Jan 1;29(1):63-80
J Biol Chem. 2013 Feb 22;288(8):5381-8
Expert Opin Investig Drugs. 2009 Aug;18(8):1061-83
Cited by 38 citations (total)
Journal Article Review
RBFOX2 as a regulatory linchpin in cancer: insights from a comprehensive review of its roles in tumorigenesis.
Electronic publication date November 18, 2024
Siqian Liao [...] Huizi Li et al.
RNA-binding proteins (RBPs) are essential regulators of RNA expression during both transcriptional and post-transcriptional processes. Recent evidence indicates that dysregulation...
Journal Article
RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma.
Electronic publication date June 3, 2024
Xiao Song [...] Shi-Yuan Cheng et al.
Widespread alterations in RNA alternative splicing (AS) have been identified in adult gliomas. However, their regulatory mechanism, biological significance, and...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Copyright
© 2021. The Author(s).